Department of Rheumatology, Aarhus University Hospital
Aarhus, 8000, Denmark
NCT Number: NCT03429426
Today, regular X-ray examination is not sufficiently sensitive for detecting progression of bone destruction in rheumatoid arthritis, but a new type of high-resolution CT scanner, the High-Resolution peripheral Quantitative Computed Tomography (HR-pQCT) can detect very early and minor joint injuries.
The purpose of this study is to use HR-pQCT techniques to look at the damage and disease activity progression in the hand and wrist joints of patients with rheumatoid arthritis.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Aarhus, 8000, Denmark
The design of the trial is an observational study with three distinct groups. At the start of the trial period and at one-year of follow-up, the trial subject will have their hand X-rayed by conventional radiography, and their metacarpophalangeal (MCP) joint and wrist scanned by HR-pQCT-Imaging. The 28-joint Disease Activity Score(DAS28-CRP), Health Assessment Questionnaire (HAQ), Visual analogue scale(VAS)-score for pain, fatigue and quality of life are performed to investigate the correlation between radiographic changes and disease activity. Blood samples are collected to investigate serological markers of bone metabolism and inflammation and the radiographic changes. The following groups are investigated:
Only the study team can determine whether someone qualifies for participation.
Rheumatoid arthritis patients Inclusion criteria
Exclusion criteria
Exclusion criteria
Exclusion criteria
Time frame: One year
Changes in bone erosions volume in mm3 by HR-pQCT-imaging from baseline to one-year follow-up, in the three groups.
Time frame: One year
Changes in volumetric bone mineral density(vBMD) in mgHA/cm3 by HR-pQCT-imaging from baseline to one-year follow-up, in the three groups.
Time frame: One year
Changes in bone erosions width in mm by HR-pQCT-imaging from baseline to one-year follow-up, in the three groups.
Time frame: One year
Changes in bone erosions depth in mm by HR-pQCT-imaging from baseline to one-year follow-up, in the three groups.
Time frame: One year
Change in Sharp/van der Heijde (SvH) score from baseline to one-year follow-up, in the three groups.
Time frame: one year
Changes from baseline to one-year follow-up in C-terminal telopeptide (CTX) in pg/mL, in the three groups.
Time frame: one year
Changes from baseline to one-year follow-up in Procollagen type 1 N-terminal propeptide (P1NP) in pg/mL, in the three groups.
Time frame: one year
Changes from baseline to one-year follow-up in Bone-specific alkaline phosphatase (BAP) in pg/mL, in the three groups.
Time frame: one year
Changes from baseline to one-year follow-up in the Tumor necrosis factor-alfa (TNF-α) in pg/mL, in the three groups.
Time frame: one year
Changes from baseline to one-year follow-up in RANK-Ligand (RANK-L) in pg/mL, in the three groups.
Time frame: one year
Changes from baseline to one-year follow-up in Osteoprotegerin (OPG) in pg/mL, in the three groups.
Time frame: one year
Changes from baseline to one-year follow-up in Osteocalcin (BGLAP) in pg/mL, in the three groups.
Time frame: one year
Changes from baseline to one-year follow-up in Sclerostin(SCL) in pg/mL, in the three groups.
Time frame: one year
Changes from baseline to one-year follow-up in Dickkopf-related protein 1 (Dkk-1) in pg/mL, in the three groups.
Time frame: one year
Changes from baseline to one-year follow-up in Interleukins 1 (IL-1) in pg/mL, in the three groups.
Time frame: one year
Changes from baseline to one-year follow-up in Interleukins 6 (IL-6) in pg/mL, in the three groups.
Time frame: one year
Changes from baseline to one-year follow-up in Interleukins 15 (IL-15) in pg/mL, in the three groups.
Time frame: one year
Changes from baseline to one-year follow-up in Interleukins 16 (IL-16) in pg/mL, in the three groups.
Time frame: one year
Changes from baseline to one-year follow-up in Interleukins 17 (IL-17) in pg/mL, in the three groups.
Time frame: one year
Changes from baseline to one-year follow-up in Interleukins 22 (IL-22) in pg/mL, in the three groups.
Time frame: one year
Changes from baseline to one-year follow-up in Interleukins 33 (IL-33) in pg/mL, in the three groups.
Time frame: one year
Changes from baseline to one-year follow-up in Chemokine ligand 11 (CCL11) in pg/mL, in the three groups.
Time frame: one year
Changes from baseline to one-year follow-up in Chemokine (C-X-C) motif ligand (CXCL13) in pg/mL, in the three groups.
Time frame: one year
Changes from baseline to one-year follow-up in Tartrate-resistant acid phosphatase 5b (TRACP 5b) in pg/mL, in the three groups.
Time frame: one year
Changes from baseline to one-year follow-up in C-reactive protein (CRP) in mg/L, in the three groups.
Time frame: one year
Disease Activity Score (DAS28-CRP) [2.0-10.0]
Time frame: one year
Health Assessment Questionnaire (HAQ) [0-3 HAQ Total Score]
Time frame: one year
Visual Analog Scale(VAS) for pain [0-100mm]
Time frame: one year
Visual Analog Scale(VAS) for fatigue [0-100mm]
Time frame: one year
Visual Analog Scale(VAS) for quality of life [0-100mm]
Time frame: one year
aBMD in the lumbar spine, and the left hip by DXA, in RA patients
Aarhus University Hospital
Other
An Observational Study of Bone Erosion Determination and Progression in Rheumatoid Arthritis Assessed by HR-pQCT and Conventional X-ray
Acronym: RACTX
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06016517
Arthritis, Arthritis, Rheumatoid
Boston, Massachusetts, United States
View Trial DetailsNCT07412704
Arthritis, Arthritis, Rheumatoid
La Jolla, California, United States
View Trial DetailsNCT04196868
Arthritis, Arthritis, Rheumatoid
Bayonne, France
View Trial DetailsNCT06246123
Arthritis, Arthritis, Rheumatoid
Cheonan, Chungcheongnam-do, South Korea
View Trial Details